Arrhythmia Research Technology will be rebranding to Micron Solutions, according to a press release posted late last week. The move comes as the company aims to associate itself with its wholly-owned subsidiary, Micron Products, which provides contract manufacturing services for medical device components which require precision machining and injection molding. Check out the full story on […]
Amniox Medical taps ex-Smith & Nephew honcho Dugan for CEO | Personnel Moves
Arrhythmia Research, Blue Belt ink supply deal
Arrhythmia Research Technology (NYSE:HRT) subsidiary Micron Products said it inked a deal to supply components for Blue Belt Technologies’ Stride unicondylar knee implant system.
Arrhythmia Research Tech closes $500k private placement
Arrhythmia Research Technology (NYSE:HRT) this month announced the close of a private placement round of funding, raising $500,000 to put toward "working capital."
Endo Health taps new CFO from Becton Dickinson | Personnel Moves
HRS13: Arrhythmia Research Technology touts new ECG device
Arrhythmia Research Technology‘s (NYSE:HRT) Signal-Averaged Electrocardiography device is 1 of only 2 ECG tests that can predict ventricular arrhythmias in patients with prior heart attacks, data from an NIH-funded multi-center clinical trial proves.
Arrhythmia names new CEO | Personnel Moves
Mobile EKG maker AliveCor appoints new president & CEO | Personnel Moves
AliveCor names Daniel Sullivan its new president, CEO and director
California mobile medical device maker AliveCor announced a shift at the helm, naming Daniel Sullivan its new president & CEO as the company sets its sights on wider commercial distribution.
Teleflex gains on acquisitions, Q1 numbers | Wall Street Beat
Shares of Teleflex (NYSE:TFX) are up today after the medical device maker revealed a pair of acquisitions and earnings well above Wall Street’s expectations.
Limerick, Pa.-based Teleflex said it inked deals to buy the EZ-Blocker pulmonary catheter technology and Axiom Technology Partners, which makes the EFx line of laparoscopic fascial closure devices.
Zimmer slides on Q1 results | Earnings Roundup
New J&J CEO Gorsky wants to grow device business | Wall Street Beat
When Alex Gorsky takes the helm at Johnson & Johnson (NYSE:JNJ) tomorrow, he’ll become responsible for a company bedeviled by a series of high-profile, big-ticket recalls, a more than $1 billion legal settlement – and blessed with the world’s largest medical device business.
